Plain-English translation of NCT07392229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The MAZINGA study is testing whether zanubrutinib, a newer type of immune-targeting medication, can help people with anti-MAG neuropathy—a rare condition where the body's immune system mistakenly attacks the protective coating around nerves, causing weakness and numbness. Researchers want to see if this medication can improve nerve function and reduce symptoms over one year of treatment. This trial involves 50 adults across multiple hospitals in Italy.
Anti-MAG neuropathy is a rare immune disease that causes progressive nerve damage and disability, and currently there are limited treatment options available. This trial exists to determine whether this medication could offer meaningful relief for patients struggling with worsening weakness and loss of feeling.
You likely qualify if…
You likely don't qualify if…
You would take the medication daily for 12 months while visiting the hospital or clinic regularly for check-ups, blood tests, and nerve function testing (electromyography). During the study, doctors will track your symptoms, strength, and nerve activity using standardized questionnaires and electrical tests. Some participants may be monitored for up to 48 months total to see long-term effects and how long benefits last.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
Italy